2023

 Clinical Trials and the Clinical Trials Regulation – impact on questions of patentability at the EPO
  James Warner and Cameron Marshall, Carpmaels & Ransford (London)

 Patent enforcement in the UPC from a life sciences perspective: what will change?
  Dr. Kai Rüting, Vossius & Partner (Munich); Daan de Lange, Brinkhof Advocaten (Amsterdam)

 AI tools for patent attorneys: hallucination or reality?
  Dr. Rachel Free, CMS Cameron McKenna Nabarro Olswang LLP (London)

 Adaptation of the description under Art. 84 EPC and the potential consequences in European patent litigation
  Dr. Stephan Neuhaus, Allen & Overy (Düsseldorf)

2022

 Advanced UP/UPC Seminar: Case Studies for the Life Science/Chemistry Sector
  Dr. Thorsten Bausch and Dr. Niels Hölder, Hoffmann Eitle (Munich)

 Plausibility as a Means to Assess Quid Pro Quo
  Dr. Hans-Rainer Jaenichen, Vossius & Partner (Munich)

 Preliminary Injunctions Today
  Dr. Andreas von Falck, Hogan Lovells (Düsseldorf)

 High Priority – Priority Entitlement in the EPO
  Dr. Derk Vos, Maiwald (Munich)

2019

 Arbitration of patent disputes in the field of life sciences
  Mr. Andrea Mondini, Times Attorneys (Zurich)

 Plausibility - A new criterion for patentability?
  Dr. Derk Vos, Maiwald (Munich)

 How to Deal with Unusual Prior Art in the Determination of Inventive Step
  Dr. Ulrike Ciesla, MLL (Zurich); Dr. Thorsten Bausch, Hoffmann Eitle (Munich)

 The changing Landscape of Patent Eligibility in the U.S.
  Dr. Kirsten A. Grüneberg, Grüneberg and Myers PLLC (Washington)

 Patenting Digital Health Inventions
  Dr. A. Dick and Dr. M. Stößel, Altmann Stößel Dick Patentanwälte PartG mbB (Mannheim)

2018

 Patents and Biodiversity Legislations - What patent practitioners need to know about the Nagoya Protocol.
  Dr. Michael Kock, dr. kock consulting (Basel)

 Transparency vs Fair Protection - Is the clinical trial-transparency initiative a deterrent to innovation?
  Dr. Lorenz Kallenbach, Corporate Patent Counsel at Merck (Darmstadt)

  U.S. Patent Rights:   Is the pendulum swinging back in favor of patent owners?
  Dr. Anthony Tridico, Finnegan (London)

 Exhaustion of Patent Rights
  Dr. Johann Pitz, Vossius & Partner (Munich)

 Hindsight bias in patent law
  Dr. Mark Schweizer, President of the Swiss Federal Patent Court

 An update on SPCs – what’s new?
  David Miller and Christopher Hamer, Mathys & Squire (London)

2017

 Guarantees /warranties in the context of IP related agreements
  Marco Stief, Maiwald (Munich)

 G 1/15 and partial priorities: consequences for divisional filing strategies
  Dr. Hans-Rainer Jaenichen and Dr. Jürgen Meier, Vossius & Partner (Munich)

 Protection of Know How, Trade Secrets and Confidential Information
  Sarah Turner, Hogan Lovells (London)

 The Judicial Exceptions And Patent Eligibility
  Dr. Kirsten A. Grüneberg, Grüneberg & Meyrs PLLC (Washington DC)

 European claim drafting: The importance (or not) of precision
  Chris Hamer, Mathys & Squire (London)

2016

 2^nd Medical Use Claims – New Indications for an old Claim Category
  Dr. U. Storz; Michalski, Hüttermann & Partner (Düsseldorf)

 Pharmaceutical & Biotech Patent Cases 2015 Year in Review
  Brian Coggio, Fish & Richardson (New York)

 Indirect Patent Infringement in UK
  Sebastian Moore, Herbert Smith Freehills (London)

 Recent Developments in the case law of the Boards of Appeal of the EPO
  Dr. Rudolf Teschemacher, Bardehle Pagenberg (Munich)

 Incentives of the Paediatric Extension Regulation: Skinny Labelling – Latest Developments
  Prof. Dr. Burkhard Sträter, Sträter Rechtsanwälte (Bonn)

2015

 Rules of Procedure in Opposition and Opposition Appeal Proceedings at the EPO - A balancing act between procedural economy
 and the right to be heard
  Dr.Eva Ehlich, Maiwald Patentanwaltsgesellschaft mbH (Munich)

 Disclaimers and Selection Inventions under EPC practice
  Dr. A. Hüttermann; Michalski, Hüttermann & Partner (Düsseldorf)

 Poisoned priorities and rays of hope from the EPO
  Dr. Tobias Bremi, Isler & Pedrazzini AG, (Zürich), Second Ordinary Judge at the Swiss Federal Patent Court

 Patent disputes at the Interface of Patent and Administrative Law in Switzerland
  Dr. Simon Holzer and Mr. Christophe Rapin, Meyerlustenberger Lachenal (Zürich)

 Strategies for Successfully Navigating Post-Grant Procedures at the USPTO
  Dr. Anthony Tridico, Finnegan (London)

 News relating to the Unitary Patent and European Patent Court
  Dr. Ulrich Blumenröder, Grünecker Patent- und Rechtsanwälte (Munich)

2014

 EU Competition Law and IPRs in Pharma
  Mr. Blaž Višnar, Case Officer at the Directorate General of Competition of the European Commission (Brussels)

 Cross-border preliminary measures in patent litigation and international arbitration in The Netherlands
  Bert Oosting, Hogan Lovells International LLP (Amsterdam)

 Disclosure and Utility Requirements in Canadian Patent Practice
  Dr. John Norman, Gowlings (Ottawa)

 The New EU Competition Rules For Licensing Agreements
  Prof. Dr. Andreas Heinemann, Dipl.-Ök., Lehrstuhl für Handels-, Wirtschafts- und Europarecht; Universität Zürich

 Compulsory Licenses
  Dr. Roberto Romandini, Max Planck Institute for Innovation and Competition (Munich)

2013

 The pros and cons of AIA - How can we make strategic use of it?
  Dr. Anthony Tridico, Finnegan (Brussels)

 The Impact of Employee Invention Law on Research and Development Co-operations
  Jens Kunzmann, Cornelius, Bartenbach, Haesemann & Partner (Cologne)

 Patent Litigation in Germany and Europe
  Philipp Neels, Wallinger, Richer, Schlotter, Tostmann (Munich)

 Boards of Appeal of the EPO - quo vadis? In the light of the Appeals to the German Constitutional Court and the Unified Patent Court Project
  Dr. U. Kinkeldey, Former Chair of a TBA at the EPO and permanent member of the EBA at the EPO

 The Unitary Patent and European Patent Court
  Dr. Ulrich Blumenröder, Grünecker Patent- und Rechtsanwälte (Munich)

 European Case Law relating to SPCs
  Dr. Stefan Danner, ZSP Patent Attorneys (Munich)

2012

 The Common Law – Unified Patent Court – Important UK Cases
  The RT. Hon. Professor Sir Robin Jacob, Faculty of Laws; University College London

 The Therasense Case – a new approach regarding inequitable conduct
 Brief overview on important points of the revision of the US patent law
  Prof. Martin J. Adelman, George Washington University Law School; Washington DC

 Where does the EU stand on Biosimilars?
  Marie Manley, Bristows (London)

 Patent Litigation in Europe – Trends and Outlook for Pharma Patents
  Dr. Andreas von Falck, Hogan Lovells (Düsseldorf)

 The Pitfalls of Art. 123 EPC - Recent Developments in Case Law
  Dr. Derk Vos, Maiwald (Munich)

 First Experiences at the Swiss Federal Patent Court
  Dr. Dieter Brändle, President of the Swiss Federal Patent Court

2011

 Introduction of the Swiss Federal Patent Court and Recent European Case Law on Selection Inventions, Divisional Applications
 and Double Patenting
  Dr. Tobias Bremi, Isler & Pedrazzini AG, Zürich; elected Judge at the Swiss Federal Patent Court

 How to efficiently perform FTO-Analysis with the help of intelligent IT
  Gary J. Speier, Schwegman, Lundberg, Woessner (Minneapolis)

 European Court of Justice on Scope of Protection of DNA Sequences (Monsanto vs. Cefetra)
  Dr. Michael Kock, Head Intellectual Property; Syngenta International AG (Basel)

 Patent Litigation in Germany – Practical Aspects of Procedural Law
  Dr. Peter Kather, Preu Bohlig & Partner (Düsseldorf)

 Patent Litigation in France – Decisions and Trends for Chemistry and Pharma Patents
  Pierre Véron, Véron & Associés (Paris)

 Research Exemptions in the US, Europe, CN and JP
  Kristof Roox, Crowell & Moring (Brussels)

2010

 Patent Mapping and Patent Landscaping
  Dr. Reinhold Nowak, CEO of OMEGA Consulting Group GmbH (Adelshofen)

 Strategic Uses of U.S. Reexamination Proceedings
  Jonathan Spadt, RatnerPrestia (Valley Forge, PA)

 Written Description Requirement in the U.S. Patent Practice
  Brian D. Coggio, Fish & Richardson P.C. (New York)

 IP Rights and Licensing – Effects on Tax Law
  Stephan Karl Schultze, LOEBA Treuhand GmbH, Lörrach

 Technology- and IP-Transfer with China
  Dr. Michael Kock, Syngenta International AG (Basel)

 Patent Law Strategies Under Indian Practice
  Pravin Anand, Anand & Anand (New Delhi)

2009

 Patent Litigation in Europe – Trends and Outlook for Pharma Patents
  Dr. Andreas von Falck, Lovells (Düsseldorf)

 Know How Protection and Patent Strategies of Globally Active Companies – Evonik Degussa Experiences
  Dr. Matthias Schäfer, Evonik Degussa GmbH (Hanau-Wolfgang)

 The Attorney always rings Twice - First Experiences with taking evidence under the Enforcement Directive in Germany
  Dr. Mathias Ricker and Dr. Uli Foerstl, Wallinger Ricker Schlotter Foerstl (Munich)

 Successfully Structuring Out-Licensing and Spin-Out Agreements by Pharma and Big Biotech:
 How to Leverage Your Assets to Increase Revenues
  Laura Anderson, Bristows (London)

 The Patenting of Antibodies and their Medical Uses under EPO Practice
  Dr. Hans-Rainer Jaenichen, Vossius & Partner (Munich)

 Patenting Stem Cells – Different Approaches in EP, DE and UK
  Dr. Jürgen Meier, Vossius & Partner (Munich)

2008

 Inequitable conduct: What it is and how to avoid it
  Prof. Brian D. Coggio, Fish & Richardson P.C. (New York)

 Patents and Public Health - What is at stake? What is the way forward?
  Dr.Felix Addor, Swiss Federal Institute of Intellectual Property (Bern)

 Licensing – Exclusive, Non-Exclusive, Sole, Minimums, Warranties – How to Avoid Pitfalls
  Prof. Dr. Heinz Goddar, Boehmert & Boehmert (Munich)

 Essential Patents / FRAND – an objection in the pharmaceutical sector?
  Dr. Walter Maiwald, Maiwald Patentanwalts GmbH (Munich)

 US Patent Infringement Case Law – Latest Developments
  Robert J. Koch, Milbank, Tweed, Hadley & McCloy LLP (Munich/Washington DC)

 Interaction between Competition and Intellectual Property Law
  Sebastian Moore and Stephen Wisking, Herbert Smith LLP (London)